Therefore, a longitudinal study that uses a series of serum NFL detections with a large number of patients will be needed to clarify the fluctuations in the serum NFL levels throughout the entire disease course and its association with the clinical progression of ALS. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.